- Home
- INVE vs VRCA Comparison
INVE vs VRCA Comparison
Compare INVE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- VRCA
- Stock Information
- Founded
- INVE 1990
- VRCA 2013
- Country
- INVE United States
- VRCA United States
- Employees
- INVE N/A
- VRCA N/A
- Industry
- INVE Computer peripheral equipment
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- VRCA Health Care
- Exchange
- INVE Nasdaq
- VRCA Nasdaq
- Market Cap
- INVE 74.2M
- VRCA 65.4M
- IPO Year
- INVE 1997
- VRCA 2018
- Fundamental
- Price
- INVE $3.50
- VRCA $0.81
- Analyst Decision
- INVE Strong Buy
- VRCA Hold
- Analyst Count
- INVE 3
- VRCA 5
- Target Price
- INVE $6.50
- VRCA $6.00
- AVG Volume (30 Days)
- INVE 99.0K
- VRCA 775.3K
- Earning Date
- INVE 08-07-2025
- VRCA 08-13-2025
- Dividend Yield
- INVE N/A
- VRCA N/A
- EPS Growth
- INVE N/A
- VRCA N/A
- EPS
- INVE 3.12
- VRCA N/A
- Revenue
- INVE $25,239,000.00
- VRCA $7,179,000.00
- Revenue This Year
- INVE N/A
- VRCA $171.87
- Revenue Next Year
- INVE $9.00
- VRCA $71.38
- P/E Ratio
- INVE $1.12
- VRCA N/A
- Revenue Growth
- INVE N/A
- VRCA N/A
- 52 Week Low
- INVE $2.86
- VRCA $0.38
- 52 Week High
- INVE $4.35
- VRCA $8.98
- Technical
- Relative Strength Index (RSI)
- INVE 63.68
- VRCA 70.98
- Support Level
- INVE $3.10
- VRCA $0.77
- Resistance Level
- INVE $3.61
- VRCA $0.67
- Average True Range (ATR)
- INVE 0.14
- VRCA 0.08
- MACD
- INVE 0.04
- VRCA 0.03
- Stochastic Oscillator
- INVE 79.25
- VRCA 81.85
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.